Global Montelukast Sodium Market Report 2024: A USD 2.24 Billion Market by 2034 at a CAGR of 15.7%, Driven by Rising Prevalence of Respiratory Diseases and Enhanced Drug Formulations [Yaho...
Merck & Company, Inc. (new) (MRK)
Last merck & company, inc. (new) earnings: 4/28 06:45 am
Check Earnings Report
US:NYSE Investor Relations:
investors.merck.com/home/default.aspx
Company Research
Source: Yahoo! Finance
The global montelukast sodium market size was estimated to be USD 0.451 billion in 2023 and is predicted to reach USD 2.24 billion by 2034 with a CAGR of 15.71% during the forecast period 2024-2034. Increased geriatric population, growing awareness of the benefits of Montelukast sodium, growing R&D investments, a greater emphasis on preventative healthcare, rising prevalence of respiratory diseases, and strategic partnerships and collaborations will significantly boost the market's growth. The increased prevalence of respiratory ailments including allergic rhinitis and asthma has greatly fueled the market for montelukast sodium. As a leukotriene receptor antagonist, montelukast reduces inflammation and bronchoconstriction to successfully treat asthma symptoms. When used for allergic rhinitis, it relieves symptoms such as itching, sneezing, and congestion of the nose. By product type, the montelukast sodium amorphous segment accounted for the highest revenue-grossing segment in
Show less
Read more
Impact Snapshot
Event Time:
MRK
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MRK alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MRK alerts
High impacting Merck & Company, Inc. (new) news events
Weekly update
A roundup of the hottest topics
MRK
News
- Merck & Co., Inc. (NYSE: MRK) had its price target raised by analysts at Truist Financial Co. from $142.00 to $143.00. They now have a "buy" rating on the stock.MarketBeat
- Merck (MRK) Q1 2024 Earnings Call Transcript [Yahoo! Finance]Yahoo! Finance
- Merck Stock Gains On Its Blockbuster Cancer Drug Keytruda, Raises Annual Outlook [Yahoo! Finance]Yahoo! Finance
- Merck (MRK) Q1 Earnings Top, Cancer Drug Keytruda Boosts Sales [Yahoo! Finance]Yahoo! Finance
- Merck (MRK) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates [Yahoo! Finance]Yahoo! Finance
MRK
Earnings
- 4/25/24 - Beat
MRK
Sec Filings
- 4/25/24 - Form 8-K
- 4/11/24 - Form ARS
- 4/11/24 - Form DEFA14A
- MRK's page on the SEC website